Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really? To me it looks like Symtomax has 18 employees and $3.6m in revenue since 3/7/2017. Not bad for a startup.
https://www.zoominfo.com/c/symtomax-sa/465816072
https://www.racius.com/symtomax-lda/
Lol. So now Symtomax has gone from 0 revenues to being able to pay people $1m each for jobs on the board?
Symtomax is no scam. All DD points to the contrary.
It's irrelevant which one is newer. One was modified on 10/21/2019, the one I just presented. The other was created and modified on 11/25/2019 so it is newer. The point is with the finding of the older one Symtomax has been presenting it to investors longer than originally thought. Symtomax is the real deal Fuzzy. Way too many big connections for it not to be and GCANrx and it's shareholders will bank big on it as well when Symtomax really gets going.
SMH. Does it even matter? What's the big deal? There are subtle differences. New, old, who cares. Just know there are two with slightly different info.
Sprycel. If the presentation is not newer why did Invictus Group switch back to an older presentation? I know for a fact that Invictus Group used to display the original presentation because I downloaded it from there. Also I've been watching Symtomax website for a long time. I don't recall Carla Maia or even João Peixoto being listed until after Symtomax updated the website yet they are not in the original presentation but are in the one I just found.
I have found a slightly different version of the Symtomax presentation. It may be newer because it is on the same site where the first presentation could be found but it says August 2019 and doesn't have Dr. Eurico Castro Alves in it but does have
Carla Maia MBA B.Eng| Country Liaison Officer and
Joao Peixoto LLM | Chief Compliance Officer
Invictus Group.
http://www.invictusgrp.net/portfolio
This one contains mock-ups of the facility and a better topography of the land. Down at the bottom it also lists some of their partnerships and Maia's company GO Engenharias is listed as well as a new one AI Labs. Artificial Intelligence.
https://www.ailab.com.au/
Pretty interesting the above site is in Australia.
I found it when looking for the site where it stated 63% of the fund has been fulfilled. I'm still looking for that but I have so much stuff it's difficult. Maybe someone could do a board search because I think I posted it at one time.
I did. They have several more people listed as well. I just did a bunch of research on this woman. She is another powerhouse in Portugal!!!
Carla Maia
https://www.symtomax.com/portugal-cannabis-producer/
https://www.linkedin.com/in/carla-maria-maia-311730174/
http://goe.com.pt/
https://www.idc-a.org/press-release-idca-chairman-meets-the-portuguese-president-on-digital-economy
Not yet. Risk = Reward. I can wait for the x and the y. Symtomax will be Tilray, Canopy type of huge and they won't want to stay private for long. ;)
Actually it means EVERYTHING. I'll take $1.00 per tab, although I think it will be much more, times 30m EU and Africa tabs, conservatively over time. Yikes! You do the math.
Symtomax...scam? LMAO. No possible way.
Eurico Castro Alves.
https://visao.sapo.pt/exame/2019-10-25-Ex-secretario-de-Estado-da-Saude-e-presidente-do-Infarmed-contratado-para-empresa-de-canabis/
"Castro Alves was also Secretary of State for Health, a position he held for about a month in the second government of Passos Coelho. He has a degree in Medicine and completed training in General Surgery in the USA, being director of the department of surgery at the Porto Hospital Center. For seven years he was a member of the Health Regulatory Authority and has a health consulting firm, WiseHS."
WiseHS
https://wisehs.eu/en/home
https://wisehs.eu/pt/formacaogdp
https://lisbon.cannx.org/wp-content/uploads/sites/81/2019/07/CV-EURICO-ENGLISH-2-1.pdf
http://www.hsmartinho.pt/template.php?id=director_clinico
Dr. Eurico Castro Alves (Former President of Infarmed I.P.)
https://www.abreuadvogados.com/en/knowledge/events/event/medical-cannabis/
This guy is very well connected and everywhere.
https://www.google.com/search?q=Eurico+Castro+Alves+wisheS&rlz=1C1GIWA_enUS593US593&sxsrf=ACYBGNTjrSwiCCxtC8lM_hlGh24TTUjE6g:1578666487433&ei=94kYXp3tGYuKggf7uaSQAw&start=0&sa=N&ved=2ahUKEwjdxM75nvnmAhULheAKHfscCTI4ChDy0wN6BAgLEC0&biw=1517&bih=904
Tic...Toc... Do you know where your shares are? Lol.
Interesting? Anyone see this? Says it was posted yesterday.
Symtomax
Lol. Wow. I'm guessing Zimbabwe didn't get that memo then.
https://www.herald.co.zw/zims-first-mbanje-plant-gets-growing/
Zimbabwe has planted its first legal hemp crop after it took steps in 2018 to decriminalise cannabis by adopting legalisation policies to tap into the opportunities that exist in this multi-billion dollar industry.
The Zimbabwe Industrial Hemp Trust (ZIHT) and British firm Eco Equity have planted the crops after winning approval from Government to undertake industrial hemp production.
The two firms were allowed to grow the hemp crop after paying a licence of around US$46 000 each.
ZIHT with its funding partner NSK Holdings and technical partner Symtomax — a Portuguese firm planted six varieties of industrial cannabis on a 10-hectare piece of land owned by the Harare Central Prison on the eastern outskirts of the capital.
Here try this one as well.
https://africanagribusiness.com/zimbabwe-kicks-off-cannabis-industry-with-prison-plantation/2517/
Don't like that one? Try MSN Africa. Oh wait they post fake news. lol
https://www.msn.com/en-xl/africa/zimbabwe/zimbabwe-kicks-off-cannabis-industry-with-prison-plantation/ar-AAIUNxJ
Aw what the heck. I guess all of Africa is in on it.
https://www.google.com/search?rlz=1C1GIWA_enUS593US593&sxsrf=ACYBGNTNastBC2ZNVhUkoDjVssRHxxzuAQ%3A1578430918150&ei=xvEUXqHJCKHH_QbmmbWADg&q=harare+prison+south+africa+hemp&oq=harare+prison+south+africa+hemp&gs_l=psy-ab.12...42907.49258..52390...0.2..0.108.437.4j1......0....1..gws-wiz.......0i71j33i22i29i30j33i160.bfOhHBFclps&ved=0ahUKEwihxLaxsfLmAhWhY98KHeZMDeAQ4dUDCAs
Need to ask yourself what FRLF is actually worth compared to peers? The sector itself, which looked stronger, is now again getting beat up.
CVSI last Q
$13.7m cash reserve
$12.6m sales
$4.1m COGS
$8.4m Gross Profit
Trading at 1.00
Authorized Shares
190,000,000
12/12/2019
Outstanding Shares
99,397,151
FRLF
$2.1m sales
$? COGS
$? Cash reserve
Authorized Shares
1,000,000,000
01/06/2020
Outstanding Shares
585,983,209
01/06/2020
FRLF worth what per share??? 1/6 CVSI... maybe??? 0 comparison. FRLF not even close to their league and CVSI is $1.00? FRLF priced right where it should be.
.10 maybe .12 a share if they can show they have improved on the COGS which IMO I hardly doubt. GL yet to prove they are worth anything at this point. We'll see. 10Q will be very telling.
GL Leaf!
IMO only. I'd start to get just a little concerned with the lack of the 10Q filing. Is the filing late due to an SEC action on FRLF? Interesting that OTCMarkets has these actions listed on their website as to why the stop sign. Rules 10b-5 and 10b5-1
"Warning! This company may not be making material information publicly available
Buying or selling this security on the basis of material nonpublic material information is prohibited under Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5 and 10b5-1 thereunder. Violators may be subject to civil and criminal penalties."
Shareholder lawsuits for violations of Section 10(b) of the Securities Exchange Act of 1934 (Exchange Act) are a common source of liability for public companies. These cases are often triggered by nothing more than a drop in stock price, after which shareholder plaintiffs allege that the change in price reflects newly public information that the company previously and improperly concealed.
Hmmm. Possibly failing to notify shareholders about Spain in an 8K which most certainly affected shareholders decisions to buy, sell or hold?
The SEC’s implementing regulation, Rule 10b-5, further defines the scope of the statutory language. The rule renders it unlawful, in connection with the purchase or sale of any security, to:
Employ any device, scheme, or artifice to defraud;
Make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made not misleading; or
Engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person.
I could be wrong but I'd certainly be concerned at this point. Pinksheets don't even have these warnings.
LMAO. STOPSIGN. Pink, no information available. GL here.
https://www.otcmarkets.com/stock/FRLF/overview
DALLAS, January 6, 2020 – GL Brands (OTCQB: FRLF) (“the Company”), a multinational hemp consumer packaged goods company and global house of brands, is pleased to announce that revenue guidance for its recently completed first fiscal quarter of 2020 ended Sept. 30, 2019 in the range of $2.1 million to $2.5 million
Awesome. Lol. Now put out the 10Q so we can see how much that revenue actually cost to produce and what the actual NET gain is.
And another investment group
http://www.invictusgrp.net/portfolio
Not the first or last country I've seen this, but looks like Symtomax also hitting up Chinese investors with the presentation.
China
https://www.rml-advisory.ch/private-assets
https://584b0793-b92b-45b5-9ba6-9836eefa77ad.filesusr.com/ugd/0d46e8_2ebc92961fa943e69077c35b8a3a9eb7.pdf
Well if it's a share selling enterprise they aren't very good at it.
State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 29,380,969 shares of common stock as of November 17, 2017.
https://www.otcmarkets.com/filing/html?id=12393135&guid=KKWvUaTdaPFhT3h
Outstanding Shares
38,664,050
12/20/2019
https://www.otcmarkets.com/stock/GCAN/security
9m shares in... 2 years??
375,000 shares per month?
Oh yeah. Their just racking in the dough for personal gain at that rate. Lol.
It's a start up. There are bills. Costs money to be OTCQB every year. Seems to me 9m shares over 2 years is pretty reasonable. Most share selling enterprises try to that every month or more.
Seems to me a real share selling enterprises O/S would look something like:
2017 - 29,380,969,
2018 - 129,380,969,
2019 - 229,380,969.
Yet here the O/S sits at 38m. Just 9m in 2 years.
Let me know if they start putting out 5 PR's trying to sell 9m a month. Till then this is far from a share selling enterprise.
Absolutely!!!
Follow the money!
Symtomax
Samantha Roman
https://peterhousecap.com/
Peterhouse Capital Limited is an integrated financial services group, dedicated to the needs of growth-orientated and entrepreneurial companies. Peterhouse is one of the leading independent small cap brokers for AIM companies, in addition Peterhouse is the largest NEX Exchange Corporate Adviser. Peterhouse is also the owner of an international discretionary asset management company and JP Jenkins, Europe’s longest established matched bargain facility.
With this unique array of complementary businesses, the Company provides a full range of advisory and broking services to Main Market, AIM and NEX Exchange Growth Market companies and to companies looking to join these, or similar, markets.
https://peterhousecap.com/wp-content/uploads/2018/07/Cannabis.pdf
High Growth Capital
? Sector: Financial Services (HASH.NEX)
? Market capitalisation: £1.0m
? Estimated gross cash: £0.55m
? IPO: July 2018
Their initial investment strategy is to invest in UK, Canadian and Australian-focused medicinal
cannabis and related products. The Company will aim to track companies in the sector whose
shares are either quoted or listed on public company stock exchanges and Recognised
Investment Exchanges.
The Company aims to provide investors with direct exposure to such companies, developing
a fully balanced and weighted tracker fund covering such UK listed cannabis companies
admitted to all UK public markets.
Management biographies
Malcolm Burne, Executive Chairman: founder of a broad range of financial companies
in stock broking, fund management and venture capital firms, and a former equity analyst
and FT journalist.
Samantha Roman, Strategic Advisor: a founder of Spot Therapeutics Inc., (2013) an
early collaborator in the cannabis ecosystem (since acquired by Canopy Growth Corp).
She is the President of ‘Credible Cannabis’ advising industry, ancillary companies and
private clients driven by science and sound business practices
Exactly!!! Symtomax is... NO JOKE!!!
Samantha Roman
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/other/13691864.html
High Growth Capital plc
(“HASH” or the “Company”)
Admission to the NEX Exchange Growth Market
The Board of the Company is pleased to announce that trading in its Ordinary Shares has commenced at 8.00 a.m. today on the NEX Exchange Growth Market ("Admission"), under ticker HASH and ISIN number GB00BPT23R97.
For avoidance of doubt and as per the announcement of 15 June 2018, the Company's ISIN (GB00BPT23R97) and SEDOL (BPT23R9) remain the same and existing share certificates remain valid and will not be replaced.
The Company’s Investment Strategy is to initially effectively become a UK, Canadian and Australian-focused medicinal cannabis and related products’ index tracker and investor. The Company will aim to track companies in the sector that are quoted or listed on public company stock exchanges and Recognised Investment Exchanges such as the NEX Exchange Growth Market. Constituents must have a business strategy focused on the medicinal cannabis industry, or other related cannabis or hemp products. The index will be equally-weighted and rebalanced on a regular basis.
On 29 March 2018, the first ever initial public offering of a company primarily focused on the cannabis sector was undertaken on the NEX Exchange Growth Market, a Recognised Investment Exchange, by Sativa Investments plc. The Company anticipates that this IPO will be a catalyst for a number of additional UK stock market listings by companies operating in the cannabis sector in the near future. It is also the aim of the Company to ensure that it provides investors with direct exposure to such companies, developing a de-facto ‘tracker’ covering such UK listed cannabis companies admitted to any and all UK public markets.
The Company will adapt its longer-term investment policy to reflect the growth of the UK-listed Cannabis market place, initially, to provide the maximum range and depth of exposure to investee companies. The Company intends to adopt a policy of acquiring up to 10 per cent. of the share capital of each company it invests into, or £150,000 worth of such equity, whichever is the lower amount, and, subject to, and, at the discretion of the Board.
Details of Directors
The full names of the Directors of the Company and positions are as follows:
Malcolm Burne, Non-Executive Chairman (Aged 74)
Malcolm Alec Burne is a serial financial markets entrepreneur who, as principle, has developed businesses in stockbroking, fund management, corporate finance and venture capital. He started his career as an investment columnist with the ‘Financial Times’ and has lived and worked in Australia, Hong Kong and Canada as well as the UK. He is a director of a number of companies in early stage venture investing and remains founder Chairman of Golden Prospect Precious Metals Limited, a quoted Guernsey based closed end investment company.
Michael Canie, Non-Executive Director (Aged 46)
As Dean and Professor of Sports Technology and Innovation at Loughborough University and a founding director of two university spin-out technology companies, Professor Caine brings considerable experience in the growth and development of innovative technology companies, as well as an extensive network within the academic and commercial sport, education and technology communities, to the role.
Marcus Yeoman, Non-Executive Director (Aged 55)
Marcus Yeoman (Non-Executive Director), is a non-executive director of reach4entertainment Enterprises plc and a previous non-executive director of GoTech. He is a non-executive director of a number of private companies which have engaged him principally to assist them with their growth strategies. His early career started with the formation of three companies in IT infrastructure and distribution, after which he moved into small company broking and corporate work with Rathbone Stockbrokers Limited and Cheviot Capital (Nominees) Limited. In 2003, Marcus established Springtime Consultants Ltd and has been acting as a consultant or non-executive director to a number of listed companies and SME ventures.
Rupert Horner, Finance Director (Aged 55)
Rupert qualified as a chartered accountant with KPMG in 1987 in London. In 1989, he joined and subsequently became a director of Thompson Investments (London) Limited, a family owned private investment vehicle. He has served as finance director of a number of both private and public companies (on the Main Market of the London Stock Exchange and AIM) including Union Square PLC, Clubhaus PLC and Secora PLC.
Samantha Roman, Managerial Advisory Committee Member
Company designate, Samantha Roman, is to be formerly appointed as Managerial Advisory Committee Member.
Samantha was a founder of Spot Therapeutics Inc., (2013) an early collaborator in the cannabis ecosystem (since acquired by Canopy Growth Corp TSE: WEED). She is the President of Credible Cannabis advising industry, ancillary companies and private clients driven by science and sound business practices. As advisor to conferences, she concentrates on the future of the industry and consumer safety. Previously, Samantha was a director at a leading financial institution and head of health and safety for an agriculture operation. She holds a Bachelor of Science Nursing (Honours) and a Master Business Administration.
Conversion of Loan Notes
On 24 May 2018, the Company announced it had raised £250,000, before expenses, via the issuance of un-secured and non-interest bearing loan notes, convertible into Ordinary Shares of the Company. The loan notes convert automatically immediately following admission to trading on NEX at, the lower of either, 0.4 pence per share or a 10 per cent. discount to the opening bid-price.
A further announcement will be made shortly outlining the conversion price, substantial shareholder information and the total voting rights.
The Ordinary Shares to be issued pursuant to the proposed Loan Note conversion will rank pari passu with the existing Ordinary Shares.
The Directors of the Company accept responsibility for the content of this announcement.
Contact details:
The Company Malcolm Burne 0207 469 0937
Mb@jpjenkins.com
NEX Exchange Corporate Adviser
Peterhouse Capital Limited
Guy Miller and Eran Zucker
020 7220 9795
Yep. Symtomax must be a scam. Lol. Samantha Roman is highly recognized as a leader in Cannabis in Canada after selling her first company to Canopy Growth.
https://ocannabiz.com/archives/speakers/samantha-roman
Who said anything about it having anything to do with US markets. My bet is on the UK.
Samantha Roman
Samantha Roman was a founder of Spot Therapeutics Inc., a pioneering cannabis producer applicant in Canada 2013. She is the first female founder in the industry to: achieve liquidity for investors via acquisition by a global leader (Canopy Growth Corp, TSE: WEED) and; be named Advisor to a NEX listed UK cannabis fund.
As Principal and President of Credible Cannabis (www.crediblecannabis.com) Samantha concentrates on advisory mandates for trailblazing companies and organizations driven by science and best business practices. In addition, her company controls and sells high valued cannabis web real estate and strategies.
Professional service firms, producers and international clients value Samantha’s systems approach. While developing the global legal cannabis sector she is committed to advancing a balanced understanding of cannabis’ use, its effects and enhancing consumer safety. At conferences and in media she discusses the future of the industry and the relationship between business success and social responsibility.
Samantha's professional experience includes; clinical practice and blue chip company management within global financial services, pharmaceuticals, medical distribution, and organic agriculture. She holds a Bachelor of Science Nursing (Honours) and a Master of Business Administration.
Who said anything about it having anything to do with US markets. My bet is on the UK.
Samantha Roman
Samantha Roman was a founder of Spot Therapeutics Inc., a pioneering cannabis producer applicant in Canada 2013. She is the first female founder in the industry to: achieve liquidity for investors via acquisition by a global leader (Canopy Growth Corp, TSE: WEED) and; be named Advisor to a NEX listed UK cannabis fund.
As Principal and President of Credible Cannabis (www.crediblecannabis.com) Samantha concentrates on advisory mandates for trailblazing companies and organizations driven by science and best business practices. In addition, her company controls and sells high valued cannabis web real estate and strategies.
Professional service firms, producers and international clients value Samantha’s systems approach. While developing the global legal cannabis sector she is committed to advancing a balanced understanding of cannabis’ use, its effects and enhancing consumer safety. At conferences and in media she discusses the future of the industry and the relationship between business success and social responsibility.
Samantha's professional experience includes; clinical practice and blue chip company management within global financial services, pharmaceuticals, medical distribution, and organic agriculture. She holds a Bachelor of Science Nursing (Honours) and a Master of Business Administration.
Shell companies do no business correct? How then is Symtomax a shell if they have already helped to plant 10 hectares in Africa with planned expansion to 90 hectares and confirmed in not one but 2 articles from different sources, one of which is a huge S. African news paper reaching several million people?
https://www.herald.co.zw/zims-first-mbanje-plant-gets-growing/
And if you look that's $3.6m per last Q or $14.4m per year for Symtomax.
Lol. 75% huh?
What's 75% of 587,000,000. That would be 440,250,000?. How on earth could the insiders even attempt to sell 1/10 of that without crashing the stock. Mark my words. 1 for 5 R/S next year is only way they could sell safely.
C'mon Houston. You're actually going to lecture me on "Maybe's" and "If's" on how a stock trades when I've been telling everyone not to buy since wait for it... .30? Yes. I just started trading yesterday. Lol. No, in all seriousness just kidding with ya above. IMO you are also one of the good guys, just stuck like some others for listening to the wrong people.
There is nothing in those charts to assume anything other than what it has done for the last 10 months. There was no "volume break" according to both charts. One day that clock might be right but it's been wrong every step of the way for 10 months. GL.
Fact Check: Not quite so simple as you claim because there are 500m Authorized not issued, and 37m Issued and outstanding. Way big difference from your completely wrong quote below.
Lol. Yep. Symtomax revenue is $3.6m greater than 0.00. Thanks for the info.
As of Q4
Employees: 18
Revenue: 3.6M
https://www.zoominfo.com/c/symtomax-sa/465816072
"Volume breakout"? Lol. "HOD"? Lol. Nothing more than it has done previously many, many, many times before only to fall again after the news of the day fades away. This supposed volume breakout is less than all previous... volume breakouts. How could anyone possibly construe this as a "volume breakout". The volume today couldn't even get back up to previous news volume spikes as noted by the volume trend line and it's called a volume breakout? Just look at the volume... chuckle. Been here, done this before at least 3 times only to see it fall.
Note worthy trading sequences:
10:59
Bid - .07 2400 sell
Bid - .07 10000 sell
Bid - drops to .062
11:41
Bid - .0745 4849 sell
Bid - .0745 7777 sell
Bid - .0745 12172 sell
Bid - .0745 5000 sell
Bid - .0745 10000 sell
Bid - drops to .057 that's right folks .057.
And please stop with the "well some of those were buys nonsense" because it wouldn't have dropped to a dramatic low bid if they were.
Then when the bid was .073 towards EOD I can't tell you how many times I saw the .73 get hit to expose the real bid at .066 which was quickly covered up by 10K at .073. No one wanted to hit .0789 for hours because that's at the top of the trend line.
Notice where the high stopped dead. Right on the trend line. No one looking at this chart could possible say "volume breakout". I'm sorry folks you just can't. Notice the spacing of those volume breakouts... chuckle. Talk about manufactured. 1,2,3 drop, 1,2,3 drop, 1,2,3 drop? We'll see.
Folks. They were still unloading .06's and some .05's before the news. All this news did was allow them to unload .07's like all other news releases have done.
And I'll leave you with this final note. Next week is Christmas week. "Beware the wolf in sheep clothing" As I said last year they will be coming for your shares. Don't fall for it. Holding? Hold fast. Buying? Put your bids in low... way low.
And a closer look. There is a reason it stopped at .079.
You as well!!
my bad sorry wasn't meant for you.
Yes, agree, according to the estimated numbers but that number below is gross and meaningless if the cost of the unit is $2.75. Which is why investors are actually waiting for the real numbers. Revenue - Cost of goods sold. Unfortunately those numbers are... delinquent.
Then put out the 10Q so investors can actual see the monetary value because if I remember correctly they put out a monetary value on the estimated revenue from the Spain Greenhouse and we all know how that worked out. Great they put out gross numbers. How much profit are they making? IMO these recent PR's are to temper the next atrocious Q. We'll see if they ever muster the cajones to actually put it out.
LMAO. Ooooh another shipment of... what?
Not to mention 2 months late just like their delinquent Q.
The Company completed its first shipment to Mexico, which included over 200,000 units of product, including Green Lotus' premium hemp oil topicals, in September 2019. The second shipment included the same quantity of Green Lotus' CBD products. The Company anticipates fulfilling a third shipment consisting of 250,000 units to Mexico by the end of October 2019 to complete its initial launch into 4,000 points of sale in Mexico.
https://www.otcmarkets.com/stock/FRLF/news/Freedom-Leaf-Wholly-Owned-Subsidiary-Green-LotusTM-Announces-Second-Successful-Commercial-Shipment-to-Mexico?id=243862
So. What's contained in those shipments? Units? WTF is a unit? Could be anything but they never tell you. Why? You'd think they would be proud to tell you what a unit is.
Whats the profit margin on these units? Is there any profit on a unit? Why are they called units? How much does each... chuckle... unit cost. How much are the ... chuckle... units selling for? These are the questions that need to be answered.
I have a couple "units" for sale too. Anyone want to buy a unit? Lol.
Just more fluff.
So I guess all that nonsense about how the old FRLF management was running FRLF like a big board stock and getting financing like the big stocks do was all meaningless gibberish? Lol. Peeps are waiting for the 10Q before buying. FACT.
Yep. 60 minute showing reversal start which will lead to much improved daily. Just waiting on the 60 minute 200 cross at .0486.
No one cares about Carlos Frias Facebook page or podcasts or PR's. What they care about is the delinquent 10Q and ANY sign of progress in it. Period. End of story.